3162 related articles for article (PubMed ID: 7499102)
21. Docetaxel (Taxotere): a review of preclinical and clinical experience. Part I: Preclinical experience.
Bissery MC; Nohynek G; Sanderink GJ; Lavelle F
Anticancer Drugs; 1995 Jun; 6(3):339-55, 363-8. PubMed ID: 7670132
[TBL] [Abstract][Full Text] [Related]
22. Docetaxel.
Cortes JE; Pazdur R
J Clin Oncol; 1995 Oct; 13(10):2643-55. PubMed ID: 7595719
[TBL] [Abstract][Full Text] [Related]
23. Docetaxel (Taxotere): single agent activity, development of combination treatment and reducing side-effects.
Pronk LC; Stoter G; Verweij J
Cancer Treat Rev; 1995 Sep; 21(5):463-78. PubMed ID: 8556719
[TBL] [Abstract][Full Text] [Related]
24. Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice.
Bissery MC; Vrignaud P; Lavelle F; Chabot GG
Anticancer Drugs; 1996 Jun; 7(4):437-60. PubMed ID: 8826613
[TBL] [Abstract][Full Text] [Related]
25. Combined effects of docetaxel and fluoropyrimidines on tumor growth and expression of interleukin-6 and thymidine phosphorylase in breast cancer xenografts.
Yamamoto S; Kurebayashi J; Kurosumi M; Kunisue H; Otsuki T; Tanaka K; Sonoo H
Cancer Chemother Pharmacol; 2001 Oct; 48(4):283-8. PubMed ID: 11710628
[TBL] [Abstract][Full Text] [Related]
26. The mechanism of action of docetaxel (Taxotere) in xenograft models is not limited to bcl-2 phosphorylation.
Kraus LA; Samuel SK; Schmid SM; Dykes DJ; Waud WR; Bissery MC
Invest New Drugs; 2003 Aug; 21(3):259-68. PubMed ID: 14578676
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of DMP 840: a novel bis-naphthalimide cytotoxic agent with human solid tumor xenograft selectivity.
McRipley RJ; Burns-Horwitz PE; Czerniak PM; Diamond RJ; Diamond MA; Miller JL; Page RJ; Dexter DL; Chen SF; Sun JH
Cancer Res; 1994 Jan; 54(1):159-64. PubMed ID: 8261436
[TBL] [Abstract][Full Text] [Related]
28. [Antitumor effect of docetaxel against human endometrial tumor cell lines].
Shakuto S; Noguchi K; Bissery MC
Gan To Kagaku Ryoho; 2005 Oct; 32(10):1437-42. PubMed ID: 16227744
[TBL] [Abstract][Full Text] [Related]
29. Comparison of antiangiogenic activities using paclitaxel (taxol) and docetaxel (taxotere).
Grant DS; Williams TL; Zahaczewsky M; Dicker AP
Int J Cancer; 2003 Mar; 104(1):121-9. PubMed ID: 12532428
[TBL] [Abstract][Full Text] [Related]
30. The taxoids: paclitaxel (Taxol) and docetaxel (Taxotere).
Pazdur R; Kudelka AP; Kavanagh JJ; Cohen PR; Raber MN
Cancer Treat Rev; 1993 Oct; 19(4):351-86. PubMed ID: 8106152
[TBL] [Abstract][Full Text] [Related]
31. The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo.
Shi B; Yaremko B; Hajian G; Terracina G; Bishop WR; Liu M; Nielsen LL
Cancer Chemother Pharmacol; 2000; 46(5):387-93. PubMed ID: 11127943
[TBL] [Abstract][Full Text] [Related]
32. Complete regression of xenografted human carcinomas by a paclitaxel-carboxymethyl dextran conjugate (AZ10992).
Sugahara S; Kajiki M; Kuriyama H; Kobayashi TR
J Control Release; 2007 Jan; 117(1):40-50. PubMed ID: 17126446
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of 6-diazo-5-oxo-L-norleucine and N-[N-gamma-glutamyl-6-diazo-5-oxo-norleucinyl]-6-diazo-5-oxo-norleucine against experimental tumors in conventional and nude mice.
Ovejera AA; Houchens DP; Catane R; Sheridan MA; Muggia FM
Cancer Res; 1979 Aug; 39(8):3220-4. PubMed ID: 572261
[TBL] [Abstract][Full Text] [Related]
34. Preclinical pharmacology of docetaxel.
Bissery MC
Eur J Cancer; 1995; 31A Suppl 4():S1-6. PubMed ID: 7577097
[TBL] [Abstract][Full Text] [Related]
35. [Development of a new tubulin-interacting agent, docetaxel (taxotere) in Japan].
Tsukagoshi S
Gan To Kagaku Ryoho; 1997 Jul; 24(9):1167-74. PubMed ID: 9239173
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of growth and metastasis of orthotopic human prostate cancer in athymic mice by combination therapy with pegylated interferon-alpha-2b and docetaxel.
Huang SF; Kim SJ; Lee AT; Karashima T; Bucana C; Kedar D; Sweeney P; Mian B; Fan D; Shepherd D; Fidler IJ; Dinney CP; Killion JJ
Cancer Res; 2002 Oct; 62(20):5720-6. PubMed ID: 12384530
[TBL] [Abstract][Full Text] [Related]
37. [Inhibition of tumor neo-angiogenesis and induction of apoptosis as properties of docetaxel (taxotere)].
Schimming R; Hunter NR; Mason KA; Milas L
Mund Kiefer Gesichtschir; 1999 Jul; 3(4):210-2. PubMed ID: 10474267
[TBL] [Abstract][Full Text] [Related]
38. [Taxotere: from yew's needles to clinical practice].
Lavelle F; Gueritte-Voegelein F; Guenard D
Bull Cancer; 1993 Apr; 80(4):326-38. PubMed ID: 7909695
[TBL] [Abstract][Full Text] [Related]
39. Risks and benefits of taxanes in breast and ovarian cancer.
Michaud LB; Valero V; Hortobagyi G
Drug Saf; 2000 Nov; 23(5):401-28. PubMed ID: 11085347
[TBL] [Abstract][Full Text] [Related]
40. Combined modality radioimmunotherapy for human prostate cancer xenografts with taxanes and 90yttrium-DOTA-peptide-ChL6.
O'Donnell RT; DeNardo SJ; Miers LA; Lamborn KR; Kukis DL; DeNardo GL; Meyers FJ
Prostate; 2002 Jan; 50(1):27-37. PubMed ID: 11757033
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
